Inhibition of Ras for cancer treatment: the search continues.

  title={Inhibition of Ras for cancer treatment: the search continues.},
  author={Antonio T Baines and Dapeng Xu and Channing J Der},
  journal={Future medicinal chemistry},
  volume={3 14},
The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment. Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic. We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer. Since approaches to directly target mutant Ras have not been successful, most efforts have… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS